Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial

Debate is around the optimal immunization regimen for cancer vaccines since too intense vaccination schedules may exhaust reactive lymphocytes. GX301 is a telomerase-based cancer vaccine whose safety and immunological effects were tested in a phase I trial applying an eight administrations schedule....

Descripción completa

Detalles Bibliográficos
Autores principales: Filaci, Gilberto, Fenoglio, Daniela, Nolè, Franco, Zanardi, Elisa, Tomasello, Laura, Aglietta, Massimo, Del Conte, Gianluca, Carles, Joan, Morales-Barrera, Rafael, Guglielmini, Pamela, Scagliotti, Giorgio, Signori, Alessio, Parodi, Alessia, Kalli, Francesca, Astone, Giuseppina, Ferrera, Francesca, Altosole, Tiziana, Lamperti, Giuseppina, Criscuolo, Domenico, Gianese, Francesco, Boccardo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571235/
https://www.ncbi.nlm.nih.gov/pubmed/34351436
http://dx.doi.org/10.1007/s00262-021-03024-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571235/
https://www.ncbi.nlm.nih.gov/pubmed/34351436
http://dx.doi.org/10.1007/s00262-021-03024-0

Ejemplares similares